Read Larry Connors' blog – Short Term Trading Strategies
Dey President Carolyn Myers, Ph.D., said: "We are very pleased to be launching Dey's highly anticipated next-generation, needle-protected EpiPen Auto-Injector. The objective of the product's new features is to give those who carry an epinephrine auto injector some additional peace of mind when it comes to the risk of anaphylaxis. We also hope that those who are at risk of anaphylaxis but currently don't carry an epinephrine auto injector will become as prepared as possible for the risk of allergen exposure."
EpiPen Auto-Injector is the number one prescribed first-line emergency auto-injector for potentially life-threatening allergic reactions known as anaphylaxis. Anaphylaxis can occur when people with allergies to food, insect stings, latex or other allergens come in contact with that allergen. Immediate access to epinephrine is critical during the first few minutes of an anaphylactic reaction.
"Prompt administration of epinephrine during a severe allergic reaction helps save lives so it's important that people not only have immediate access to a self-injected epinephrine but know how to properly use it," said Dr. Phil Lieberman, Clinical Professor of Medicine and Pediatrics, University of Tennessee College of Medicine. "This new EpiPen Auto-Injector offers enhancements to make it easier for people to administer epinephrine quickly and properly in an emergency situation."
The next-generation EpiPen Auto-Injector introduces built-in needle protection, making EpiPen the only epinephrine auto-injector with no exposed needle before and after use. Other benefits of the re-designed EpiPen Auto-Injector include:
-- An ergonomically-designed, easy-to-grasp oval barrel with illustrated
instructions that allow for rapid understanding and proper use of EpiPen
Auto-Injector. The oval shape also prevents the device from rolling out
of reach during an emergency;
-- one-step flip-top carry case that allows for rapid, single-handed
removal;
-- bright orange colors and arrows to help quickly identify the needle end
of the device and reduce the risk of accidental thumb puncture.
Importantly, any patient that currently carries or has recently received an EpiPen or EpiPen Jr. Auto-Injector should continue to carry that EpiPen Auto-Injector until their current pen is used or reaches its expiration date. Upon renewal of their next EpiPen Auto-Injector prescription, patients will automatically receive the next generation EpiPen Auto-Injector.
About Anaphylaxis
Anaphylaxis is a severe allergic reaction that involves a number of body systems and can be fatal within minutes, either through swelling that shuts off airways or through a significant drop in blood pressure. Anaphylaxis occurs in people with allergies to certain foods, insect stings, medications, latex or other allergens. As many as 15% of Americans - up to 12 million people - have an allergy that may put them at risk for anaphylaxis. There are up to 2,000 episodes of anaphylaxis per every 100,000 people in the U.S. each year. The precise incidence of anaphylaxis is unknown because this serious, life-threatening condition is believed to be underreported. The vast majority of deaths from anaphylaxis occur in individuals who do not receive epinephrine in time.
About EpiPen Auto-Injector
EpiPen and EpiPen Jr. (0.3 and 0.15 mg epinephrine) Auto-Injectors are for the emergency treatment of severe allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for patients who are at increased risk for these reactions.
EpiPen and EpiPen Jr. Auto-Injectors are designed for you to use immediately in an emergency, to treat an allergic reaction fast and give you time to get to a hospital or medical center. EpiPen and EpiPen Jr. Auto-Injectors are not a substitute for emergency medical treatment.
As with any medication, EpiPen Auto-Injector has an expiration date printed directly on the unit and shelf carton and should therefore be replaced when the unit expires. The product should be stored at room temperature and never refrigerated or kept where it might be exposed to extreme temperatures, such as in the glove compartment of a car.
Dey Pharma, L.P., the distributor of EpiPen Auto-Injector, offers patient support through free membership in the EpiPen Center for Anaphylactic Support (CAS) Program(TM). This program provides helpful tips, resources and an expiration reminder program. Information on how to join can be found on the patient insert dispensed with the product and by visiting www.epipen.com.
Important Safety Information
Each EpiPen Auto-Injector contains a single dose of a medicine called epinephrine, which you inject into your outer thigh. DO NOT INJECT INTRAVENOUSLY. DO NOT INJECT INTO YOUR BUTTOCK, as this may not be effective for a severe allergic reaction. In case of accidental injection, please seek immediate medical treatment.
Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.
Side effects may include an increase in heart rate, a stronger or irregular heartbeat, sweating, nausea and vomiting, difficulty breathing, paleness, dizziness, weakness or shakiness, headache, apprehension, nervousness, or anxiety. These side effects usually go away quickly, especially if you rest. If you have high blood pressure or an overactive thyroid, these side effects may be more severe or longer lasting. If you have heart disease, you could experience chest pain (angina). If you have diabetes, your blood sugar levels may increase after use. If you have Parkinson's disease, your symptoms may temporarily get worse.
Talk to your doctor to find out if you should be prescribed an EpiPen or EpiPen Jr. Auto-Injector.
About Dey
Dey Pharma, L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, severe allergic reactions and psychiatric disorders. The company puts patients first and facilitates efficient, cost-effective partnerships with customers. For more information, please visit www.dey.com.
About Mylan
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.
EpiPen(R) is a registered trademark of Dey Pharma, L.P.
See accompanying full prescribing information (PI) or visit www.epipen.com for full PI.
SOURCE Dey Pharma L.P.
http://www.dey.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.